Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 2026
Podium presentation by Co-Founder and Chief Research Officer Laura Read More
Largest Real-World Evidence Study in Early-Stage Breast Cancer; FLEX Surpasses 25,000 Patients
Agendia’s landmark FLEX Study reaches a major enrollment milestone, Read More
Agendia Announces Definitive, Mandatory Swiss Health Insurance Reimbursement for MammaPrint
Effective 1 July 2026, Switzerland’s FOPH completes its review Read More
Genomic Profiling with MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer GalleryGenomic Profiling with MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer
Genomic Profiling with MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer
FLEX Study data shows that patients with MammaPrint High Read More
- Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer Gallery
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
Additional research highlights integration of BluePrint molecular subtyping and Read More
- Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer Gallery
Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer
Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer
Multivariate analyses reveal that pathologic complete response is associated Read More
- Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress Gallery
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress
Poster presentations highlight the prognostic value of MammaPrint + Read More
- Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer Gallery
Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
Multicenter study of over 1000 females with breast cancer, Read More
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Read More
Agendia to Showcase MammaPrint and BluePrint Utility in Guiding Anthracycline Therapy at the 2025 San Antonio Breast Cancer Symposium
Four additional poster presentations from the ongoing real-world FLEX Read More
